Wu Zhijie, Qin Xiusen, Zhang Yuanxin, Luo Jian, Luo Rui, Cai Zonglu, Wang Hui
Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
Gastroenterol Rep (Oxf). 2023 Oct 24;11:goad061. doi: 10.1093/gastro/goad061. eCollection 2023.
mutations (mutmut) are unfavorable prognostic factors for colorectal cancer (CRC) metastases to the liver and lungs. However, their effects on the prognosis for patients with synchronous peritoneal metastasis (S-PM) of CRC after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are controversial. In the study, we aimed to determine the effects of mutmut on the prognosis for patients with S-PM who received CRS.
A total of 142 patients diagnosed with S-PM between July 2007 and July 2019 were included in this study. The demographics, mutmut status, overall survival (OS), and progression-free survival (PFS) of the patients were evaluated. The Kaplan-Meier method and log-rank test were used to estimate the difference in survival between groups.
Among 142 patients, 68 (47.9%) showed mut and 42 (29.5%) showed mut. The median OS values were 8.4 and 34.3 months for patients with mut and wild-type, respectively (<0.01). However, status was not significantly associated with median OS (=0.76). Multivariate analysis revealed carcinoembryonic antigen, CRS, HIPEC, and mut as independent predictors for OS. Based on these findings, a nomogram was constructed. The C-index was 0.789 (95% confidence interval, 0.742-0.836), indicating good predictive ability of the model. Furthermore, the 1- and 2-year survival calibration plots showed good agreement between the predicted and actual OS rates. The area under curves of the 1- and 2-year survival predictions based on the nomogram were 0.807 and 0.682, respectively. Additionally, mut was significantly associated with lower PFS (<0.001).
mut is an independent prognostic risk factor for S-PM. The established nomogram predicted the OS of patients with CRC having S-PM with high accuracy, indicating its usefulness as a valuable prognostic tool for the designated patient cohort.
突变(mutmut)是结直肠癌(CRC)肝转移和肺转移的不良预后因素。然而,它们对接受细胞减灭术(CRS)和腹腔内热化疗(HIPEC)后发生同步腹膜转移(S-PM)的CRC患者预后的影响存在争议。在本研究中,我们旨在确定mutmut对接受CRS的S-PM患者预后的影响。
本研究纳入了2007年7月至2019年7月期间诊断为S-PM的142例患者。评估了患者的人口统计学特征、mutmut状态、总生存期(OS)和无进展生存期(PFS)。采用Kaplan-Meier法和对数秩检验来估计组间生存差异。
142例患者中,68例(47.9%)显示突变,42例(29.5%)显示野生型。突变型和野生型患者的中位OS值分别为8.4个月和34.3个月(<0.01)。然而,状态与中位OS无显著相关性(=0.76)。多因素分析显示癌胚抗原、CRS、HIPEC和突变是OS的独立预测因素。基于这些发现,构建了一个列线图。C指数为0.789(95%置信区间,0.742-0.836),表明该模型具有良好的预测能力。此外,1年和2年生存校准图显示预测的和实际的OS率之间具有良好的一致性。基于列线图的1年和2年生存预测的曲线下面积分别为0.807和0.682。此外,突变与较低的PFS显著相关(<0.001)。
突变是S-PM的独立预后危险因素。所建立的列线图能够高精度地预测发生S-PM的CRC患者的OS,表明其作为指定患者队列的有价值的预后工具的实用性。